** Specialty pharma firm 60 Degrees Pharmaceuticals' SXTP.O shares rise 5.6% to 63 cents in afternoon trade
** Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.
** Arakoda is an antimalarial drug for the prophylaxis of malaria in patients aged 18 years and older in the U.S.
** The drug is sold under the brand name Kodatef in Australia
** The drug is not approved for use in the U.S.
** SXTP plans to import a five-month supply of Kodatef while increasing manufacturing of Arakoda over long term
** Co says the two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features
** In the last 12 months, stock has fallen 80.2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。